The invention discloses four novel crystal forms H1, H2, H3 and H4 of sofosbuvir, and a method for preparing the four crystal forms. The structures and the lattice parameters of the four novel crystal forms of the sofosbuvir are determined by monocrystal X-ray diffraction analysis; characteristic peaks of the crystal form H1 are formed at the diffraction angles 2theta of 4.9 degrees, 6.6 degrees, 7.1 degrees, 8.2 degrees, 9.6 degrees, 16.5 degrees, 19.0 degrees, 19.2 degrees, 19.9 degrees, 24.9 degrees and the like; the characteristic peaks of the crystal form H2 are formed at the diffraction angles 2theta of 6.7 degrees, 7.0 degrees, 9.7 degrees, 19.1 degrees, 19.3 degrees, 19.8 degrees, 20.3 degrees, 24.9 degrees, 25.1 degrees, 25.6 degrees and the like; the characteristic peaks of the crystal form H3 are formed at the diffraction angles 2theta of 5.1 degrees, 6.7 degrees, 7.1 degrees, 9.6 degrees, 15.8 degrees, 17.2 degrees, 19.3 degrees, 19.9 degrees, 20.7 degrees, 24.9 degrees and the like; and the characteristic peaks of the crystal form H4 are formed at the diffraction angles 2theta of 5.5 degrees, 5.6 degrees, 10.0 degrees, 10.9 degrees, 10.9 degrees, 16.6 degrees, 19.8 degrees, 20.0 degrees, 20.4 degrees, 25.0 degrees and the like. The four novel crystal forms of the sofosbuvir respectively have the advantages of excellent physical and chemical properties, good stability, good solubleness, simpleness in preparation and operation and the like.